Research programme: antioxidant response element activators - RocheAlternative Names: ARE activators; Keap1-Nrf2 pathway modulators
Latest Information Update: 29 Oct 2014
At a glance
- Originator InterMune
- Developer Roche
- Class Peptides; Small molecules
- Mechanism of Action Antioxidants; NF E2 related factor 2 stimulants
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Research Fibrosis
Most Recent Events
- 01 May 2014 Early research in Fibrosis in USA (unspecified route)